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INTRODUCTION
Traditionally, most patients at increased 
risk of a thromboembolism have been 
treated with vitamin K antagonists, 
an oral anticoagulation therapy (OAT) 
that requires careful monitoring and 
dose adjustment to ensure the clotting 
tendency of the blood (assessed using 
the international normalised ratio [INR]) 
stays within a specified target therapeutic 
range.1 The consequences of over- or 
under-coagulation can be grave, with OAT 
recognised as one of the medicine groups 
that most frequently causes preventable 
harm and hospital admission.2 
In the UK, OAT monitoring services are 
commissioned locally, with a variety of 
service designs being utilised; the majority 
of patients attend monitoring clinics at their 
general practice or local hospital.3 Clinic-
based monitoring can be time-consuming 
and costly, both to the patient and the health 
service. However, with the development of 
portable measuring devices that analyse 
capillary samples it is now possible for 
patients to self-monitor their own OAT (also 
called self-testing) and adjust their OAT 
dosage (self-management).4 
Clinical trials have indicated that 
self-monitoring is a safe and effective 
intervention.5 Within these trials, 
standardised measures have demonstrated 
statistically significant improvements 
in treatment-related quality of life;6–11 
however, patient experience of self-
monitoring has not been studied in-depth. 
Furthermore, a significant number of 
patients who are offered the opportunity to 
self-monitor decline or discontinue shortly 
after initiation;12 this suggests there are 
gaps in health professionals’ understanding 
of how best to train and support patients 
embarking on OAT self-monitoring.13 As 
a result, this study aimed to undertake 
interviews with patients who were self-
monitoring in order to learn more about 
their experiences, to identify the barriers 
and facilitators encountered and to produce 
a set of recommendations on how best to 
support such patients.
METHOD
Participant recruitment
The Cohort Study of Anticoagulation Self-
Monitoring (CASM) was established to 
investigate whether the positive results 
achieved in clinical trials of anticoagulation 
self-monitoring were translated into 
a ‘real-world’ setting. The full details of 
the methods and results are published 
elsewhere.14 In brief, 299 people who had 
decided to self-monitor their OAT were 
recruited as they purchased a monitor (the 
CoaguChek® S or XS), either as a first 
or replacement model, from the major 
UK distributor (Roche) and followed-
up for 12 months. The cohort, therefore, 
contained members that were new to, or 
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Supporting patients to self-monitor their  
oral anticoagulation therapy:
recommendations based on a qualitative study of patients’ experiences
continuing with, self-monitoring. The level 
of anticoagulation control among this self-
selected sample was very good, with few 
adverse events. Discontinuation rates were 
lower than anticipated, based on clinical 
trial data, with 267/296 (90.2%) who began 
self-monitoring still doing so at 12 months. 
In-depth interviews were conducted 
with a sample of participants once they 
had completed their 12-month follow up. 
Among this self-selected sample, the 
current — sometimes ad hoc — support 
available appears adequate to enable them 
to self-monitor successfully. A purposive 
sampling strategy was used to ensure that 
a range of backgrounds, opinions, and 
experiences were studied. Recruitment 
continued until no new themes emerged. 
All interviews were conducted by the same 
researcher.
Interviews
A topic guide was developed, based on 
issues that had arisen during the cohort 
follow up; it included experiences of: 
• self-monitoring anticoagulation therapy;
• healthcare support;
• training provided;
• decision making;
• knowledge; and 
• quality assurance. 
Semi-structured interviews were 
conducted in participants’ homes or over 
the telephone and lasted 30–75 minutes. 
They were digitally recorded, transcribed, 
and checked to ensure accuracy.
Analysis 
Analysis ran concurrently with data 
collection to allow refinement of the 
interview schedule. A framework approach 
was used to enable both anticipated and 
novel themes emerging from the transcripts 
to be identified. NVivo software (version 9) 
was used to store and organise the data. A 
coding framework was developed — initial 
coding was undertaken independently by 
two researchers to ensure all areas were 
covered — and refined using the constant 
comparison method. The One Sheet of 
Paper analysis method was used to compile 
all the issues raised for a single code and 
these were grouped to form themes.15 
RESULTS
Participants
Of 34 CASM participants approached, 26 
agreed to be interviewed (older and male 
participants were less likely to agree) 
Table 1 summarises their characteristics 
as collected at the cohort study baseline. 
Interviewees tended to live in less-deprived 
neighbourhoods (median Index of Multiple 
Deprivation Score 2010 of 10.4) and 73% 
had a professional qualification and/or 
a degree, generally reflecting the CASM 
cohort as a whole. Seven interviews were 
conducted over the telephone due to the 
interviewees’ distal location from the 
Oxford-based research team.
Starting to self-monitor
Prior to self-monitoring, the interviewees 
had few worries about using the monitor; 
however, the reality, at least initially, did 
not align with the stress-free procedure 
described by the manufacturer. One patient 
said that ‘It must have taken me about 20 
goes to actually get it right the first time,’ 
(ID336, female, 36 years), while another 
said ‘It was ridiculous … I was getting really 
despondent’ (ID351, female, 73 years). 
Problems using the lancet to achieve 
a sufficiently large blood sample, and 
applying it correctly to the test strip within 
the time limit, were encountered. The fact 
that patients were taking ‘blood thinners’ 
added to their bewilderment: 
‘I did think … “this is hopeless, I can’t get the 
blood out, it’s just a waste of time”.’ (ID342, 
male, 48 years) 
Others felt personally responsible for the 
problems they were experiencing: 
‘The manual was very clear, written in very 
idiot-proof language, and then I’ve screwed 
up.’ (ID350, male, 32 years) 
These feelings were compounded by the 
use of multiple test strips: 
‘It [the monitor] came with a pack of five 
strips and I think I messed up every strip 
How this fits in
Clinical trials have indicated that oral 
anticoagulation therapy (OAT) self-
monitoring is safe and effective, but little 
is known about what patients think of 
the process and their experiences of it. 
This study found that, despite sometimes 
ad-hoc support, self-monitoring had a 
positive effect on participants’ lives. Better 
training and robust support systems 
would have helped address a number 
of problems that were encountered and 
will, therefore, be important if OAT self-
monitoring becomes more widely available. 
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and I got a bit panicky then.’ (ID333, female, 
63 years)
Over time (sometimes a very short 
time) some individuals found that using 
the monitor became less of an ordeal. 
One male participant explained that ‘It’s 
awkward at first, but […] the more you do 
it, the more easy it becomes really,’ (ID338, 
male, 55 years) 
An older female participant said: 
‘I don’t feel apprehensive about it now, I 
just go ahead and do it.’ (ID351, female, 
73 years)
For others, however, there were hints 
that, despite use of the device seeming to 
get easier, it still required some emotional, 
as well as physical, effort: 
‘I’ve got much more confident now and I 
don’t feel quite so anxious.’ (ID332, female, 
66 years)
Training
Although the instruction booklet and DVD 
supplied by the manufacturer were felt to 
be helpful, the opportunity for in-person 
training was welcomed: 
‘I know you can ring the manufacturer and 
they’re very good, but it’s different, isn’t it 
when you’re on the other end of the phone? 
It’s not quite having somebody face to face 
to see you actually physically doing it.’ 
(ID332, female, 66 years) 
Training was helpful in overcoming initial 
problems and extended beyond practical 
guidance to emotional support: 
‘I had to go back twice because I was 
getting myself in a bit of a state about it and 
he [the anticoagulation clinic nurse] … very, 
very, reassuring he was.’ (ID340, female, 
78 years) 
The atmosphere in the anticoagulation 
clinic was less tense than at home. One 
participant said she thought she:
'... was more relaxed because it was in a 
controlled environment and somebody else 
was there, an expert was there.’ (ID333, 
female, 63 years) 
The clinic offered an opportunity to 
observe practices and to ask questions: 
‘It was a two-way job. [They would ask] 
“What do you think?” Now that was 
educational.’ (ID211, male, 76 years) 
Some used the clinic practices as 
a template for their subsequent self-
monitoring behaviour: 
‘We’ve got into the routine that […] the day 
that we do […] is normally a Friday — only 
because I used to go to the clinic on the 
Friday.’ (ID239, male, 68 years)
Interviewees also educated themselves 
to supplement the variable levels of support 
and training available: 
‘I’d researched that [the monitor] fully and 
looked at all the videos and stuff and, by 
the time the machine came, you know, I 
just opened it up and I could use it straight 
away.’ (ID338, male, 55 years) 
Self-monitoring test results
Generally interviewees trusted the results 
produced by their monitor; its accuracy was 
only doubted if the results were outside the 
participant’s target range. A phase-in period, 
when the monitor was used alongside clinic 
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Table 1. Participants’ characteristics (n = 26)
Characteristic (assessed at cohort baseline) n (%)a
Demographics  
 Median age, years (range) 55 (32–78) 
 Male, n (%) 10 (38.5) 
 Median number of medications, n (range)  4 (1–25)
Occupation, n (%)  
 Working full time 8 (30.8) 
 Working part time 5 (19.2) 
 Retired 6 (23.1) 
 Unable to work 4 (15.4) 
 Home carer 2 (7.7) 
 Unemployed 1 (3.8)
Condition requiring OAT (%)  
 Thrombosis  11 (42.3) 
 Mechanical heart valve 8 (30.8) 
 Atrial fibrillation 4 (15.4) 
 Antiphospholipid syndrome 3 (11.5)
Self-monitoring characteristics  
 Median duration of self-monitoring, months (range) 1.0 (1.0–6.3) 
 Received in-person self-monitoring training, n (%) 19 (73.1) 
 Under care of an anticoagulation service, n (%) 17 (65.4) 
 Median time in therapeutic range, % (range) 82.7 (37.2–98.6) 
 Median oral anticoagulation knowledge score (range)b 18 (12–20)
Dose adjustment status, n (%)  
 Self-testing 15 (57.7) 
 Self-managing 8 (30.8) 
 Collaborative 3 (11.5)
aUnless otherwise specified. bn = 25, maximum score = 20, assessed at 12 months. OAT = oral anticoagulation 
therapy.
testing, was valued by those with limited 
previous experience of the technology: 
‘Three months or more of running it side 
by side and then we [the interviewee and 
his GP] decided that the readings were 
so close that, yeah, it was alright.’ (ID342, 
male, 42 years) 
A key motivation for self-monitoring was 
to keep a closer eye on INR levels. However, 
this was not always the reassuring process 
anticipated, as the results obtained required 
interpretation: 
‘Although it [the monitor] comes with a 
lovely DVD and it explains everything and it 
tells you to do everything, then you think you 
got this result … and then, “what do I do with 
it now?”’ (ID201, female, 39 years) 
Knowing how to react, and being able to 
do so in a timely manner, was valued. This 
helped mitigate any negative emotional 
feelings associated with the result: 
‘[It was] fine, because I had everything 
around me to know what to do immediately 
… I mean obviously it wasn’t good that it was 
so low … but it is quite empowering.’ (ID281, 
female, 42 years) 
‘If I can contact the INR clinic I’m not 
too worried because I know that we can 
increase the dose and, obviously, sort that 
out pretty quickly.’ (ID333, female, 63 years)
Out-of-range results could cause 
feelings of disappointment: 
‘[I felt] annoyed with myself for, like, not 
dosing myself correctly, but I think I’ve 
learnt now, with a bit more experience, that 
it’s a pretty random drug and there’s no 
point in beating yourself up over it.’ (ID350, 
male, 32 years) 
Others recognised that such results 
generate work: 
‘For months it was up, it was down, it was 
up, it was down, changing the dosage and, 
you know, it was frustrating thinking, “Why 
is it messing?”’ (ID357, female, 55 years)
Routines and reminders
Some interviewees talked of developing a 
self-monitoring routine: 
‘It took a bit of tuning to find the right time 
and the right place to do it […] I started off 
doing it in the mornings and worked out that 
that wasn’t the right way forward.’ (ID350, 
male, 32 years) 
A minority were, however, less organised:
'Suddenly I get a guilty conscience, yeah, 
“Oh God, I’d better do it.”’ (ID211, male, 
76 years)
And reminder systems were frequently 
used: 
‘I write it in big red writing, I put “BLOOD” on 
my calendar.’ (ID340, female, 78 years) 
Embedded within the routine was record 
keeping: 
‘When I take the test, not only do I fill in a 
reading in my yellow book, but I also write 
it down in my diary as well and … the date 
when I need to do my next test.’ (ID368, 
male, 69 years) 
Most interviewees demonstrated high 
levels of medication adherence: 
‘I take it like clockwork … I have one of the … 
daily drug organisers, so I always set that up 
on a weekly basis.’ (ID336, female, 45 years) 
In addition, family members helped; one 
participant explained that her ‘husband 
makes up the week’s drugs into little pots.’ 
(ID263, female, 54 years)
Some individuals were also able to 
transfer skills learned from living with other 
conditions to self-monitoring their INR: 
‘I test with the diabetic [blood glucose self-
monitoring kit], it’s a very similar thing.’ 
(ID263, female, 54 years) 
A variety of testing frequencies were 
reported, balancing the reassurance of the 
result and the work required to achieve it: 
‘Once or twice she’s [the practice nurse] 
said, “Well I suggest you check a bit sooner” 
because obviously [laughs] I like to leave it 
as long as I can.’ (ID239, male, 68 years) 
Those with stable INR levels were advised 
to leave up to 12 weeks between tests. 
This presented challenges in terms of both 
remembering to do the test and how to use 
the monitor: 
‘Cos you’re not using it very often you tend 
to forget and that’s when the panic sets in.’ 
(ID379, male, 46 years) 
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‘I guess the biggest challenge is always 
just remembering to do it.’ (ID327, male, 
49 years)
Lifestyle
OAT has numerous dietary interactions 
and the same self-discipline and effort 
that was demonstrated in developing a 
self-monitoring routine extended to 
interviewees’ lifestyles. There was, however, 
a workable balance to be made: 
‘I love vegetables, I love spinach, I love 
cranberries, broccoli. They say you should 
try and keep it all even but it’s very difficult.’ 
(ID333, female, 63 years) 
Disruptions included holidays, work, 
family, and social commitments. As one 
interviewee explained: 
‘It is hard to maintain an absolutely steady 
INR […] short of having an absolutely 
monastic lifestyle …’ (ID327, male, 49 years). 
However, necessary compromises were 
made when integrating self-monitoring 
behaviour into daily lives, and those with a 
less-consistent lifestyle were able to track 
the consequences more closely: 
‘It hasn’t changed my lifestyle in any way 
at all but it monitors my lifestyle.’ (ID211, 
male, 76 years) 
For a younger interviewee this was 
associated with his pre-illness identity: 
‘Maintaining self-testing makes me feel like 
I’m a normal person that can do anything I 
want.’ (ID350, male, 32 years) 
There was some evidence that self-
monitoring led to an increase in risky 
behaviour: 
‘[Prior to self-monitoring] I think you tend 
to be more careful about what you eat and 
you’re a bit paranoid really … whereas now, 
if I just thought, “Oh, I’ll eat so and so”, I can 
always leave it 2 or 3 days and have a check 
to see if it has affected it adversely.’ (ID338, 
male, 55 years) 
However, this was limited and one 
individual’s response was more typical of 
the cohort: 
‘It never crossed my mind and I don’t 
think I would want to do that, to be honest 
… I’d rather take it [the OAT] and be, like, 
proactive and make sure it’s okay before I do 
something, not afterwards.’ (ID346, female, 
33 years) 
Alcohol intake was discussed by several 
interviewees: 
‘The big thing about warfarin is you can’t 
have a drink and, oh, you’ve got to be very 
consistent, and then the last thing I can be is 
consistent [laughs].’ (ID352, male, 55 years) 
This man’s lifestyle was discordant with 
his desire for a stable INR. He explained 
that he ‘… wanted to be absolutely in range, 
absolutely, you know. I’d like things to be 
exact’ and had begun to adjust his dose to 
rectify his behaviour and improve his INR 
control. He believed that:
‘If I have done something silly I can just do 
a quick check on it.’ (ID352, male, 55 years)
These dosage adjustments were against 
the wishes of the clinic. 
Dose adjustment
A meta-analysis of trial data suggested that 
the clinical benefits of OAT self-monitoring 
may be greatest for patients managing their 
own dose adjustments;5 as such, this study 
investigated attitudes towards this. A major 
barrier experienced was a lack of healthcare 
professional support:
‘I wouldn’t mind doing it myself, but I think 
that’s taking it out their hands and out of 
their control, and that’s not what they want.’ 
(ID357, female, 55 years) 
Most clinics with an established self-
monitoring service required patients to sign 
a contract stating they would not adjust their 
own OAT: 
‘It sets out just what they expect of me and 
what I would expect of them as well. It’s very 
clear.’ (ID338, male, 55 years) 
Self-testing meant interviewees were 
able to avoid physically attending the clinic, 
which was often a key motivation for self-
monitoring. 
When the method for receiving dosing 
advice worked well, the drive to self-manage 
was further reduced: 
‘I’d be quite happy to do it [self-manage] 
but then I don’t have any problems dealing 
with the hospital either because they’re so 
professional.’ (ID281, female, 42 years) 
In addition, some interviewees gained 
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reassurance from being in regular contact 
with the clinic: 
‘I do feel confident, a bit, sort of, more 
secure knowing they [the clinic staff] are 
there. That might be just transferring my, 
the responsibility somewhere else.’ (ID330, 
female, 66 years)
However, several interviewees described 
difficulties in accessing dosing advice: 
‘You think that you’ve got this wonderful 
machine, you can get on with your life … but, 
you know, you’re still ringing up the doctors 
saying, “Look it’s 4.5 today. What do I do?”’ 
(ID339, female, 49 years) 
Following a 3-day delay in getting advice, 
she was provided with a dosing algorithm 
by her haematologist (her ‘prayer book’) and 
began to self-manage. In her opinion:
‘Without guidelines … it doesn’t work. Once 
I got those guidelines, you know, I’m happy. 
I’m a lot better, [a] more-positive person.’ 
(ID339, female, 49 years)
The use of dosing algorithms was limited. 
Other interviewees reviewed previous 
dosing decisions or utilised a more ‘trial-
and-error’ approach: 
‘There seems to be no rocket science to this, 
you know; if the reading’s too high you take 
a bit less, if the reading’s too low you take a 
bit more.’ (ID327, male, 49 years) 
In some cases, family and friends stepped 
in to also check doses: 
‘There’s two of us, albeit I do it, but we 
[interviewee and wife] do have a chat about 
the dosage.’ (ID239, male, 68 years)
‘I was very much controlling it and running it 
myself, they [father and friend] were just my 
sort of … double-checkers.’ (ID350, male, 
32 years) 
Interviewees recognised the responsibility 
of altering their own dose, with one 
participant commenting that:
‘It’s like being on insulin … they’re both 
quite dangerous materials.’ (ID307, female, 
59 years) 
However, first-time dose adjustment was 
sometimes unplanned, unprepared for, and 
in response to weaknesses in the dosing 
advice system: 
‘For some reason between 5 o’clock on 
Friday night and 8 o’clock Monday morning 
you’re very much on your own with the NHS 
GP practice.’ (ID307, female, 59 years) 
Other reasons for informally managing 
dose adjustments included pre-empting 
advice: 
‘I was sort of doing something I know 
that they would have asked me to, but 
then perhaps it’s not right.’ (ID332, female, 
66 years) 
In addition, some interviewees preferred 
a more personal approach than those 
provided by the computer dosing programs 
used by some clinics because:
‘… you have a bit more of a gut feeling about 
yourself’ (ID330, female 66 years). 
The range of acceptable INR results was 
often different to, and/or narrower than, the 
conventionally accepted target therapeutic 
ranges. For example, participant 357’s 
target range was between 2.0 and 3.0, 
however she felt: 
‘If it could just stay at 2.5 that would be 
fantastic, but it’s 2.7, 2.3, the last test I did it 
was 2.0.’ (ID357, female, 55 years) 
‘They [the clinic staff] don't like me being 
above 4, so I like to be 3.6–3.8.’ (ID352, male, 
52 years) 
Some felt the therapeutic range was 
arbitrary and disagreed with taking remedial 
action only once it had been breached, while 
two interviewees self-managed by altering 
their diet rather than their OAT dosage: 
‘I’d rather eat the green vegetables and get 
my INR naturally down.’ (ID307, female, 
59 years)
‘I sort of force a lot of greens down myself 
[laughs], and if it’s [the INR’s] the opposite 
way, I’ll have another drink or I’ll have some 
alcohol cos I know that will bring it back 
up again as well. So, I’m doing that really 
instead of going to the clinic in a way, if I’m 
honest.’ (ID332, female, 66 years)
DISCUSSION
Summary
Interviewees described OAT self-monitoring 
as a generally positive experience. Key 
difficulties at the outset of self-monitoring 
included using the monitor and gaining 
health professional agreement and/or 
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ongoing support to do so. Over time, most 
interviewees successfully established a 
balance between remembering their self-
monitoring routine, reflecting on their INR 
levels, and being conscious of their lifestyle, 
without becoming obsessed by it. They 
embedded personalised self-monitoring 
behaviour within their daily lives. 
Strengths and limitations 
To the authors’ knowledge, this is the first 
in-depth study of people self-monitoring 
their OAT that provides insights into their 
experiences. Patients purchasing their 
own monitoring devices — and therefore 
eligible for the CASM study — were younger 
than typical anticoagulant clinic attendees 
and well educated. Although they are not 
representative of all patients that could be 
offered self-monitoring in the future, their 
experiences provide an insight into this 
previously understudied area. 
Comparison with existing literature
In accordance with an earlier study of 
people with diabetes, interviewees reported 
that self-monitoring could be hard work.16 It 
was, however, viewed as a more favourable 
alternative to attending potentially inflexible, 
overcrowded clinics that were unable to 
accommodate their work, family, and social 
commitments 
Although those with stable INR levels 
expended less effort self-monitoring 
than those with fluctuating INR levels, 
the latter group reaped greater practical 
rewards by not having to attend frequent 
clinic appointments. The description of 
self-monitoring becoming ‘normal’ and 
interviewees developing a feel for it echoes 
the experience of patients self-monitoring 
their blood pressure.17 The range of 
emotions and actions triggered by self-
monitored test results also concurs with 
those described by patients self-monitoring 
chronic obstructive pulmonary disease.18
A few interviewees reported that managing 
multiple concomitant conditions made self-
monitoring easier by providing transferable 
skills, unlike a sample of patients with 
hypertension who felt overwhelmed.19 
However, self-monitoring still relies 
on the ability of individuals to effectively 
communicate with health professionals 
regarding test results, predominantly 
when they are aberrant. This presents 
difficulties, particularly in the out-of-hours 
setting, when access to advice is limited 
and patient inertia and anxiety can lead to 
ill-advised decision making. The need for 
reassurance regarding self-management 
dosing decisions has also been observed in 
diabetes self-management.20 
The discrepancy between the clinically 
accepted target range and the patient 
target range has also been observed in 
the main CASM study14 and in diabetes 
self-monitoring.21 In addition, Meier et al 
previously demonstrated that a narrow 
range does not necessarily improve control 
and, therefore, self-monitoring patients 
could be undergoing additional stress and 
workload for no clinical benefit.22 
Implications for research and practice
Box 1 outlines recommendations for the 
Box 1. Recommendations to improve training and support based on 
the narratives of interviewees
Organisational
• Ensure staff have experience of using the monitor so in-depth support can be provided
• Implement a robust support system, including out-of-hours care if possible
Initial training
•  Suggest patients bring a buddy to the initial training — someone who can subsequently provide  
support and reassurance at home
Training skills
• Offer advice on how to achieve a sufficiently large blood drop
• Include skills for effective medication adherence and record keeping
• Encourage reflection on how patients can translate the training into their daily lives
• Acknowledge lifestyle variations and disruption to routine; reflect on ways to mitigate their impact
Training content
• Reiterate lifestyle factors that affect oral anticoagulation therapy
• Explain the therapeutic range and the risks of being outside it
• Ensure that the therapeutic range is agreed and clearly documented by both patients and staff
• Provide reassurance about the problems encountered during the initial period
• Acknowledge the limitations of any support system
• Consider a phase-in period for those beginning to self-manage
• Review dosing decisions made by the patient
Ongoing support
• Agree a frequency for follow-up, either by appointment, e-mail, or telephone contact
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training and support of patients beginning 
to self-monitor their OAT based on the 
study findings. Feelings towards self-
management were often ambivalent and, for 
some, it was interpreted as ‘going it alone’ 
— a rebranding to ‘shared management’ 
should perhaps be considered to reflect 
the typical situation where patients manage 
on a day-to-day basis with support from 
health professionals being available if there 
are any problems. In addition, a phase-in 
period, in which a patient runs their dosing 
suggestions past a health professional, 
could help develop patients’ skills.
Another area that warrants further 
research is the use of diet to ‘naturally’ 
manage their INR. Although some 
interviewees felt this was preferable 
to adjusting their medication, the 
consequences could be unpredictable. How 
common this practice is, and whether it 
could — or should — be incorporated into 
self-monitoring dosing guidelines, could be 
considered.
In some cases, dosing and testing 
algorithms developed for clinic use were 
being applied to self-monitoring patients. 
Interviewees were being asked to leave up 
to a 12-week gap in between tests, which led 
to some anxiety and difficulty operating the 
monitor. These algorithms were developed 
to balance patient safety with clinic workload. 
By not physically attending the clinic, this 
balance has been altered and, therefore, 
specific testing frequency advice for self-
monitoring patients could be applied.23 
Among this self-selected sample, the 
current — sometimes ad hoc — support 
available appears adequate to enable them 
to self-monitor successfully. However 
better, more consistent training, and robust 
support systems would have alleviated a 
number of problems encountered. Based 
on the interviewees’ experiences, a set of 
recommendations has been developed for 
improved support. Better support systems 
will become more important if OAT self-
monitoring becomes more widely available.
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